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Articles
Effect of second timed appointments for non-attenders of 
breast cancer screening in England: a randomised 
controlled trial
Prue C Allgood, Roberta Maroni, Sue Hudson, Judith Offman, Anne E Turnbull, Lesley Peacock, Jim Steel, Geraldine Kirby, Christine E Ingram, 
Julie Somers, Clare Fuller, Anthony G Threlfall, Rhian Gabe, Anthony J Maxwell, Julietta Patnick, Stephen W Duffy
Summary
Background In England, participation in breast cancer screening has been decreasing in the past 10 years, approaching 
the national minimum standard of 70%. Interventions aimed at improving participation need to be investigated and 
put into practice to stop this downward trend. We assessed the efect on participation of sending invitations for breast 
screening with a timed appointment to women who did not attend their irst ofered appointment within the NHS 
Breast Screening Programme (NHSBSP).
Methods In this open, randomised controlled trial, women in six centres in the NHSBSP in England who were 
invited for routine breast cancer screening were randomly assigned (1:1) to receive an invitation to a second 
appointment with ixed date and time (intervention) or an invitation letter with a telephone number to call to book 
their new screening appointment (control) in the event of non-attendance at the irst ofered appointment. 
Randomisation was by SX number, a sequential unique identiier of each woman within the NHSBSP, and at the 
beginning of the study a coin toss decided whether women with odd or even SX numbers would be allocated to the 
intervention group. Women aged 50–70 years who did not attend their irst ofered appointment were eligible for the 
analysis. The primary endpoint was participation (ie, attendance at breast cancer screening) within 90 days of the date 
of the irst ofered appointment; we used Poisson regression to compare the proportion of women who participated 
in screening in the study groups. All analyses were by intention to treat. This trial is registered with Barts Health, 
number 009304QM.
Findings We obtained 33 146 records of women invited for breast cancer screening at the six centres between 
June 2, 2014, and Sept 30, 2015, who did not attend their irst ofered appointment. 26 054 women were eligible for 
this analysis (12 807 in the intervention group and 13 247 in the control group). Participation within 90 days of the irst 
ofered appointment was signiicantly higher in the intervention group (2861 [22%] of 12 807) than in the control 
group (1632 [12%] of 13 247); relative risk of participation 1·81 (95% CI 1·70–1·93; p<0·0001). 
Interpretation These indings show that a policy of second appointments with ixed date and time for non-attenders 
of breast screening is efective in improving participation. This strategy can be easily implemented by the screening 
sites and, if combined with simple interventions, could further increase participation and ensure an upward shift in 
the participation trend nationally. Whether the policy should vary by time since last attended screen will have to be 
considered.
Funding National Health Service Cancer Screening Programmes and Department of Health Policy Research 
Programme.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
An important indicator of the public health impact of the 
National Health Service Breast Screening Programme 
(NHSBSP) in the UK is the participation rate, deined as 
the percentage of women invited for screening who are 
screened adequately within 180 days of invitation 
(usually referred to as uptake in oicial reports). In 
England, participation following routine invitation fell 
from 74·4% in 2004–05 to 71·3% in 2014–15,1 and we are 
seeing a decline for the fourth consecutive year in a row, 
approaching the national minimum standard of 70%. 
In particular, participation among women invited for 
their prevalent (irst) round of screening has decreased 
by an even greater amount (from 70·1% in 2004–05 to 
63·3% in 2014–15).1 Participation in breast cancer 
screening also tends to be lower in areas of socioeconomic 
deprivation than in wealthier areas.2,3
The NHSBSP invites women aged 50–70 years to 
mammographic screening every 3 years. The invitation 
letter includes a screening appointment with a given 
date, time, and place. An age eligibility extension to 
invite women aged between 47 years and 73 years is 
currently being trialled.4 The usual practice for 
non-attenders of the irst ofered appointment is to send 
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them a second invitation letter, which can vary: some 
centres supply open invitations, asking women to 
telephone to make an alternative appointment; whereas 
others routinely ofer second timed appointments, with 
date, time, and place stipulated. The Department of 
Health has advised NHS England that the approach with 
second timed appointments should be used.5 Second 
timed appointments are NHSBSP policy, although this 
approach is not universally followed.
Although some women might not attend their 
screening appointment because they have made an 
informed choice not to do so, some of them will not 
attend for other reasons. These women might ind a 
second timed appointment more beneicial than an 
open invitation because it does not require any efort to 
book a new appointment with the screening centre. 
Previous indings suggest that participation is greater 
when a second timed appointment is given to 
non-attenders,6,7 but further investigations are needed to 
identify the women who would be most and least likely 
to respond to the second invitation. For example, 
someone who has not attended their last three screening 
appointments might not attend whatever the form of 
the second invitation.
In a randomised trial published in 1998, Stead and 
colleagues6 found that the efect of second timed 
appointments declined with increasing time since last 
screen, and in a more recent observational study, Hudson 
and colleagues7 noted the same association, at least in 
absolute terms, in north London. The eicacy of this 
approach has not been investigated in a randomised trial, 
or quantiied with precision, in the current target 
population for screening. Therefore, we did a randomised 
trial of second timed appointments versus open 
invitations for non-attenders within the NHSBSP, 
powered to obtain signiicant results within subgroups of 
time since last screen.
Methods
Study design and participants
This open, two-arm, randomised controlled trial was done 
in six screening sites in England (Derby, Hull, Plymouth, 
Sheield, southeast London, and west London) for diferent 
time lengths between June 2, 2014, and Sept 30, 2015. We 
chose these sites because we already had links in terms of 
research on and evaluation of the screening programme. 
Our prior constraints were that we wanted substantial 
numbers both within and outside London and areas of 
varying socioeconomic status. We excluded three screening 
centres where we were already conducting another trial of 
pre-appointment reminders. The protocol is available in 
the appendix (pp 4–20).
Women were invited to breast screening in batches of 
varying size but typically several hundreds. The date a 
batch was set up (ie, the list of women to be invited was 
compiled), was deined as the date the screening episode 
was opened for each woman in that list. For an individual 
woman, her screening episode is closed when she attends 
for screening or after 180 days if she does not attend. 
Batches of women invited to routine breast cancer 
screening were randomly assigned (1:1) to be sent either a 
second appointment with a ixed date and time 
(intervention) or an open invitation (control) in the event 
of non-attendance at the irst ofered appointment. 
Research in context
Evidence before this study
We searched the PubMed database with the keywords “breast 
cancer”, “breast screening”, “appointment”, and 
“non-attenders” for articles in English published between 
Jan 1, 1990, and Dec 31, 2016. This search retrieved 
eight papers, of which six were not considered relevant after 
title or abstract review. In 1998, Stead and colleagues 
compared second appointments with ixed date and time 
versus open second invitations for non-attenders of breast 
cancer screening in a randomised controlled trial in one 
breast screening centre in England, inding an increased 
participation rate with second timed appointments. 
Although the quality of the trial was good, its indings might 
not apply to current practice and target populations for 
screening since these have changed in terms of age and 
might have changed in terms of social support and 
employment status. In 2016, Hudson and colleagues 
reported the results of an observational study in north 
London comparing timed and non-timed second 
appointments, showing increased participation with timed 
appointments. We identiied no trials of second timed 
appointments for non-attenders from outside the UK breast 
screening programme.
Added value of this study
Our randomised controlled trial assessed the efects of sending 
invitations for breast cancer screening with a second timed 
appointment to women who did not attend their irst ofered 
appointment. Unlike previous studies on this subject, the trial 
was done at a national level (six centres across England) in 
2014–15. We could therefore analyse the eicacy of the 
intervention depending on a woman’s location and level of 
socioeconomic deprivation since the sites in the study covered 
a wide range of socioeconomic status levels.
Implications of all the available evidence
Our indings show the positive efects of second timed 
appointments on attendance for breast cancer screenings. 
The results are of policy interest for early detection of breast 
cancer, because a simple change in the procedure of addressing 
non-attenders of breast cancer screening invitations could 
result in more women being screened.
See Online for appendix
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After randomisation, the analysis was restricted to women 
aged 50–70 years. Women who self-referred for screening, 
women on an early recall protocol, and women who were 
invited because of a high risk of breast cancer were not 
randomised. Some women had more than one recorded 
invitation in the study period, which resulted in multiple 
records in the dataset. For these women, the irst invitation 
date was used for reference and participation was based on 
the irst attendance date (if any)—ie, only one of the 
multiple records was kept. Other exclusions that were 
judged to be necessary were women invited to screening 
outside the study period of the screening sites; observations 
with previous screening appointment more recent than 
the irst ofered appointment or date of the screening 
episode being opened; and observations with a date on the 
invitation letter for a previous round of screening more 
recent than the date on the current invitation letter. We also 
excluded women who participated but had missing dates 
of attendance, because in those cases it was not possible to 
determine whether they had attended within 90 days of 
their irst ofered appointment or within 180 days of their 
episode being opened (or neither).
Women were not informed of the study or asked to give 
consent for three reasons. First, the intervention was a 
minor variation in invitation practice, which was already 
standard procedure in some areas of England. Second, 
previous notiication of a possible variation to the second 
letter of invitation might change the women’s behaviour 
and defeat the purpose of the study. Finally, limiting the 
study to those interested in participating would render the 
results non-generalisable. The study was approved by the 
London Bloomsbury Research Ethics Committee.
Randomisation and masking
Within each screening centre, every invited woman was 
allocated a unique number, known as the SX number. At 
the beginning of the study, a coin toss by the chief 
investigator (SWD) decided that women with an odd SX 
number would be allocated to the intervention group 
(second timed appointment), whereas women with an 
even SX number would be allocated to the control group 
(open second invitation). This is a pseudorandomisation 
approach. Thus, there was no masking; however, the 
endpoint required no subjective judgment. Women who 
received the wrong intervention for their group 
assignment (eg, women randomly assigned to the control 
group who received a second timed appointment letter 
by administrative error) were marked with an error code 
but were still included in analysis.
Procedures
Women who did not attend their irst ofered appointment 
were lagged as such by staf at that clinic on the National 
Breast Screening System (NBSS). Subsequently, 
administration staf identiied the non-attenders in 
NBSS who were sent a second invitation within 2 weeks 
of the non-attended irst appointment. 
The intervention consisted of an invitation to a second 
appointment with ixed date and time. The control group 
received a second invitation that consisted of a letter with 
a telephone number that the women should call to rebook 
the missed screening appointment. Diferences between 
the two letters were kept to a minimum so that women 
receiving second timed appointment letters did not feel 
pressurised into attending their screening appointment if 
they had made the decision not to participate. Second 
timed appointments had to be allocated to non-attenders 
within 90 days of the missed appointment.
Because many practices already used second timed 
appointments for non-attenders of breast cancer screening, 
this study merely represented a minor variation in routine 
practice. Data were pseudonymised, removing identifying 
data items such as month and day of birth and postcode, 
before being sent to the Centre for Cancer Prevention 
(Wolfson Institute of Preventive Medicine, Queen Mary 
University of London), where analyses were done.
Outcomes
The primary endpoint was participation (ie, attendance) 
within 90 days of the irst ofered appointment. The key 
secondary endpoint was participation within 180 days of 
the screening episode being opened, used formally in the 
programme as a measure for calculating participation 
rates (usually referred to as uptake in reports). The 
endpoint was determined locally and objectively as 
whether or not the invitee attended for screening. Both 
endpoints were assessed once data collection was 
completed on March 1, 2016. Other secondary endpoints 
were subgroup analyses by prevalent (irst) or incident 
(subsequent) screen status, by time since last attended 
screen, and by index of multiple deprivation and age. 
An economic analysis is also planned, but as a separate 
exercise, since this analysis will be a major analytic efort. 
Statistical analysis
On the assumption that 40% of women who received their 
irst invitation letter would not attend their screening 
appointment, we required 90% power for a diference of 
20% (intervention group) versus 15% (control group) of 
those re-invited participating within 90 days. We also 
assumed that 20% of invitees would be non-attenders at 
their last routine screening; that 15% would not have 
attended for three screening episodes or more; and that 
10% would not have attended for four episodes or more. 
These proportions were approximations derived from 
Ofman and colleagues’ study8 and from the 10% never-
attenders observed in the West Midlands screening 
histories project.9 We required 80% power in all the 
subgroups for a diference of 14% (intervention) versus 
10% (control) in non-attenders at their last routine 
screening, of 10% versus 7% in those who had not attended 
for three screening episodes or more, and of 2% versus 1% 
in those who had not attended for four screening episodes 
or more. These proportions corresponded to requirements 
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of 1252, 1085, 1422, and 2515 individuals per group in each 
of the four categories, respectively. Thus, we required at 
least 10 060 non-attenders per group in total (corresponding 
to approximately 50 300 women invited to irst screening 
appointment in the two groups). We asked participating 
centres to recruit substantially more women than this 
number as a failsafe measure.
The diference in participation between the two groups 
was compared with Poisson regression for the primary 
and key secondary endpoints, ofset by the total numbers 
of invitees. This analysis yielded relative risks (RRs) and 
95% CIs for participation, and likelihood ratio tests for 
signiicance. We also did prespeciied subgroup analyses 
by prevalent or incident screen status, by time since last 
attended screen, and by the 2010 Index of Multiple 
Deprivation (IMD, based on a woman’s postcode).10 
National quintiles of IMD were used. Formal tests for 
heterogeneity of the efect of the intervention by prevalent 
or incident status or by socioeconomic status on 
attendance were also done. Primary analysis and subgroup 
analyses were by intention to treat, so that women who 
received the wrong type of letter for their trial group were 
retained in the analysis as if they had received the correct 
letter. Other women who were potentially excludable but 
were kept in the intention-to-treat analysis were those who 
were being screened at the time of extraction of the 
dataset, who were permanently or temporarily under care, 
who died, who moved away, who were not known at their 
recorded address, who attended for screening but for 
some reason were not screened, who had been recently 
screened, or whose reason for attendance or non-
attendance was missing or coded as “other”. These 
potentially excludable women were more likely to be 
identiied in the intervention group than in the control 
group, since the ofer of a timed appointment was more 
likely to prompt the invitee to inform the service that she 
had moved away or had already been recently screened. 
We also estimated the efect of the intervention in each 
site separately, as a post-hoc exploratory analysis. All 
analyses were done with Stata/IC version 13.1. This trial is 
registered with Barts Health, number 009304QM.
Role of the funding source
The Department of Health Policy Research Programme 
was given the opportunity to comment on this report 
before submission for publication. One author (JP) was 
employed by the funding source but only before the 
results became available to the authors. The sponsors 
and funders of the study had no role in data collection, 
data analysis, data interpretation, study design, or writing 
of the report. The corresponding author had full access 
to all the data in the study and had inal responsibility for 
the decision to submit for publication.
Results
The dataset received from the six screening centres had 
33 146 records of women invited for screening at diferent 
times between June 2, 2014, and Sept 30, 2015, who did not 
attend their irst appointment (see appendix p 3 for details 
of recruitment by centre). Women were followed up for 
more than 180 days after their episode in the current round 
of screening was opened, and the trial was ended when we 
estimated that the number of women recruited was larger 
than the one required by our power calculations. 7092 (21%) 
of the 33 146 records were excluded after randomisation 
because of the reasons stated in the Methods—eg, 
ineligible age or date of invitation, missing attendance 
record, or multiple records for the same woman (3520 in 
the intervention group vs 3572 in the control group; igure). 
Of the remaining 26 054 women, 12 807 (49%) had been 
randomly assigned to receive the intervention of a second 
timed appointment letter, and 13 247 (51%) to receive an 
open invitation letter. Characteristics of women included 
in the analysis were similar between groups (table 1). Most 
women in both groups were younger than 60 years of age 
and came from more deprived socioeconomic areas (IMD 
quintiles 1 and 2; table 1).
586 (5%) of 12 807 women in the intervention group 
and 52 (<1%) of 13 247 women in the control group 
received the incorrect invitation letter for their group but 
were still included in the intention-to-treat analysis as if 
they had received the correct letter. 455 (4%) women in 
the intervention group and 119 (<1%) women in the 
control group were judged to be potentially excludable, 
because of the nature of the intervention (as noted in the 
Methods section). The majority of these women were 
either recently screened and so invited in error (121 [21%] 
of 574), had missing reason for non-attendance 
Figure: Trial profile
SX=a sequential unique identiier of each woman within the NHS Breast Screening Programme. *Some records had 
more than one reason for exclusion. 
16 327 records of women with odd
 SX numbers randomly 
assigned to timed 
appointment (intervention)
3520 records excluded*
    2482 outside screening range 
  (50–70 years)
    110 duplicates for the same 
  woman
    147 duplicates for the same 
  woman in the same batch
    867 outside study period
    34 with incongruences in 
  dates
    44 with missing date of 
  attendance
12 807 women analysed
16 819 records of women with even 
 SX numbers randomly 
assigned to an open invitation 
letter (control)
3572 records excluded*
    2551 outside screening range 
  (50–70 years)
    146 duplicates for the same 
  woman
    54 duplicates for the same 
  woman in the same batch
    958 outside study period
    8 with incongruences in 
  dates
    24 with missing date of 
  attendance
13 247 women analysed
33 146 records of non-attenders 
 receiving second invitation letters
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(162 [28%]), or were not known to be or no longer living 
at the address held (194 [34%]). These women were also 
retained in our intention-to-treat analyses.
In total, 4493 (17%) of 26 054 women participated in 
breast cancer screening within 90 days of the date of 
their irst ofered appointment. A signiicantly higher 
proportion of women in the intervention group 
participated within 90 days than did women in the 
control group (2861 [22%] of 12 807 vs 1632 [12%] of 13 247; 
RR 1·81 [95% CI 1·70–1·93], p<0·0001; table 2). A higher 
proportion of women in the intervention group than in 
the control group also met the secondary endpoint of 
participation within 180 days of the screening episode 
being opened (RR 1·77 [95% CI 1·67–1·88], p<0·0001). 
Similar results were obtained in a post-hoc per-protocol 
analysis and an analysis excluding the women deemed 
potentially excludable (data not shown).
Overall, 12 817 (49%) of 26 054 women were ofered a 
prevalent screen (6300 in the intervention group vs 
6517 in the control group) and 13 237 (51%) women were 
ofered an incident screen (6507 in the intervention 
group vs 6730 in the control group). To take into account 
the fact that the prevalent screen includes women who 
have been invited before but have never attended, we irst 
analysed younger women in the prevalent round (ie, 
those aged 50–52 years). In this subgroup, participation 
within 90 days of the irst ofered appointment was 
signiicantly greater for women in the intervention group 
than in the control group (table 3); participation within 
180 days of the episode being opened supported this 
result. Next, we analysed data for prevalent screen 
women aged 53–70 years, who had never previously 
attended. Although numbers were small, participation at 
second invitation was still signiicantly higher in the 
intervention group than in the control group (table 3).
Participation data for incident screen women aged 
53–70 years who had attended any time previously are 
shown in table 4 by time since last attended screen before 
the date of the irst ofered appointment for this screening 
episode. Age intervals were adjusted accordingly (eg, only 
women aged 56–70 years were included in the group who 
last attended their screening 6–9 years before their irst 
ofered appointment). Despite numbers of women 
participating diminishing with increasing time since last 
attendance, all results were signiicantly in favour of the 
intervention, even for women who had attended 
previously but 9 years or more before their irst ofered 
appointment (table 4). For women who had last attended 
1–3 years previously, the expected proportion of women 
participating in screening within 180 days in the 
intervention group if there had been no efect of the 
intervention is 32% (attendance in the control group) of 
2853 (number invited in the intervention group, n=912). 
Therefore, the efect of 2853 second timed appointments 
was generating 495 (ie, 1407 [the number of attendees in 
the intervention group]–912 [the number expected of 
attendees]) attended screens. Thus, in this group about 
six (2853/495) second timed appointments would have to 
be ofered per additional participant attending screening. 
The corresponding numbers of second timed 
appointments required per additional participant are six, 
15, and 26 for women whose last attendance was 
3–6 years, 6–9 years, and 9 or more years before their 
current irst ofered appointment, respectively, calculated 
as for those attending 1–3 years previously.
Formal tests for heterogeneity of the efect of the 
intervention by prevalent or incident status were 
signiicant (p<0·0001 for participation within 90 days of 
the irst ofered appointment and within 180 days of the 
episode being opened). Separate results for prevalent and 
incident screens can be seen in tables 3 and 4. Although 
the relative efects are larger in the prevalent screen 
women, the absolute diferences in participation are 
larger in the incident screen women (tables 3 and 4).
Intervention group 
(n=12 807)
Control group 
(n=13 247)
Screen status
Prevalent 6300 (49%) 6517 (49%)
Incident 6507 (51%) 6730 (51%)
Age (years)
50–59 7484 (58%) 7842 (59%)
60–70 5323 (42%) 5405 (41%)
Median (IQR) 58 (53–64) 58 (53–63)
IMD quintile*
1 3395 (27%) 3623 (27%)
2 3645 (28%) 3703 (28%)
3 2864 (22%) 2978 (22%)
4 1946 (15%) 2028 (15%)
5 939 (7%) 891 (7%)
Missing 18 (<1%) 24 (<1%)
Site
Derby 2398 (19%) 2355 (18%)
Hull 2120 (17%) 2233 (17%)
Plymouth 2456 (19%) 2611 (20%)
Southeast London 1595 (12%) 1638 (12%)
Sheield 1207 (9%) 1185 (9%)
West London 3031 (24%) 3225 (24%)
Data are n (%) unless otherwise stated. *2010 Index of Multiple Deprivation (IMD) 
from most deprived to most aluent.
Table 1: Characteristics of study groups
Intervention 
group 
(n=12 807)
Control 
group 
(n=13 247)
Absolute difference 
in attendance
RR (95% CI) p value
Within 90 days of irst 
ofered appointment
2861 (22%) 1632 (12%) 10% 1·81 (1·70–1·93) <0·0001
Within 180 days of 
episode opened
3054 (24%) 1784 (13%) 10% 1·77 (1·67–1·88) <0·0001
Data are number who participated (%) unless otherwise stated. RR=relative risk. Percentages have been rounded up.
Table 2: Participation at second invitation for all women in the trial
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Results did not vary substantially by age group (data not 
shown). Results by national IMD quintile are shown in 
table 5. We excluded 42 women who had missing IMD data 
from this analysis (18 in the intervention group and 24 in 
the control group). The irst two quintiles (1 and 2), 
corresponding to the most deprived populations, have 
higher RRs than the other quintiles for participation within 
90 days of the irst ofered appointment and participation 
within 180 days of the episode being opened. From the 
third to ifth quintiles, RRs decrease for more aluent 
women. However, it should be noted that the absolute 
diferences in participation between the two groups were 
similar, at around 10%, in all quintiles. Results were highly 
signiicant in all quintiles (p<0·0001 in all cases).
Intervention group Control group Absolute difference in 
attendance
RR (95% CI) p value
50–52 years
Number invited 2017 2072 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 347 (17%) 147 (7%) 10% 2·42 (1·99–2·95) <0·0001
Within 180 days of episode opened 369 (18%) 163 (8%) 10% 2·33 (1·93–2·80) <0·0001
53–70 years
Number invited 4283 4445 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 283 (7%) 82 (2%) 5% 3·58 (2·80–4·58) <0·0001
Within 180 days of episode opened 307 (7%) 97 (2%) 5% 3·28 (2·61–4·13) <0·0001
Data are number who participated (%) unless otherwise stated. RR=relative risk. Percentages for the diference in attendance have been rounded up.
Table 3: Participation at second invitation for prevalent screen women, by age group
Intervention 
group
Control group Absolute difference in 
attendance
RR (95% CI) p value
Attended any time previously
Number invited 6507 6730 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 2231 (34%) 1403 (21%) 13% 1·64 (1·53–1·78) <0·0001
Within 180 days of episode opened 2378 (37%) 1524 (23%) 14% 1·61 (1·51–1·73) <0·0001
Aged 51–70 years who attended 1 to <3 years previously
Number invited 2853 2992 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 1307 (46%) 876 (29%) 17% 1·56 (1·43–1·71) <0·0001
Within 180 days of episode opened 1407 (49%) 956 (32%) 17% 1·54 (1·42–1·68) <0·0001
Aged 53–70 years who attended 3 to <6 years previously
Number invited 1633 1638 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 568 (35%) 306 (19%) 16% 1·86 (1·62–2·14) <0·0001
Within 180 days of episode opened 590 (36%) 327 (20%) 16% 1·81 (1·58–2·08) <0·0001
Aged 56–70 years who attended 6 to <9 years previously
Number invited 529 582 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 71 (13%) 39 (7%) 7% 2·00 (1·35–2·97) <0·0001
Within 180 days of episode opened 76 (14%) 45 (8%) 7% 1·86 (1·28–2·69) <0·0001
Aged 59–70 years who attended ≥9 years previously
Number invited 471 453 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 35 (7%) 16 (4%) 4% 2·10 (1·16–3·81) 0·01
Within 180 days of episode opened 37 (8%) 18 (4%) 4% 1·98 (1·12–3·48) 0·02
Data are number who participated (%) unless otherwise stated. RR=relative risk. Percentages for the diference in attendance have been rounded up.
Table 4: Participation at second invitation for incident screen women, overall and by time since last attendance
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In our post-hoc exploratory analyses, the intervention 
signiicantly increased participation at all study sites 
(p<0·0001 in all centres; appendix p 2) compared with 
that in the control group. The efect of the intervention 
was highest in southeast London (RR for participation 
within 90 days of the irst ofered appointment 2·27 
[95% CI 1·90–2·72]), which had the highest proportion 
of women in the two most deprived  IMD quintiles 
(3249 [87%] of 3738), and only 53 (1%) women in the 
two most aluent quintiles. By contrast, the efect of the 
intervention was smallest in Plymouth (RR 1·55 [95% CI 
1·36–1·77]), where 3595 (50%) of 7190 women were in 
the two most deprived IMD quintiles and 1706 (24%) were 
in the two most aluent quintiles.
Discussion
In this study, the intervention of inviting non-attenders 
of breast cancer screening to a second appointment 
with a ixed date and time caused an absolute increase 
in participation of 10·3% compared with an open 
invitation, which would translate to an increase in 
participation of 3%, since around 30% of invitees to a 
irst appointment were non-attenders.1 Most women 
included in our analysis were younger than 60 years of 
age and came from more deprived socioeconomic 
areas.
A limitation of this study was that more than 20% 
of women were excluded after randomisation. Most 
excluded women were outside the screening age range, 
so this factor is unlikely to be a source of bias. Moreover, 
although the six sites were spread across England, they 
might not be representative of the English population 
overall. However, we have no reason to believe that this is 
the case, and the primary result was similar in all centres. 
Also, we used pseudorandomisation, allocating to trial 
group by whether the SX number was odd or even. 
However, because SX numbers are not assigned in a 
systematic way by screening centres, the practice should 
allow valid comparison of trial groups. The control group 
was larger than the intervention group—ie, there were 
more women with even SX numbers. Since the SX 
numbers used for allocation in this trial are assigned 
strictly sequentially at irst invitation to the programme, 
we are unsure why this diference occurred. We have 
been unable to identify a systematic factor or staf action 
that could have caused this imbalance, although centres 
with more error codes for the sending of the wrong letter 
were also those with the larger imbalances between the 
Intervention group Control group Absolute difference 
in attendance
RR (95% CI) p value
IMD quintile 1 (most deprived)
Number invited 3395 3623 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 639 (19%) 353 (10%) 9% 1·93 (1·69–2·20) <0·0001
Within 180 days of episode opened 682 (20%) 386 (11%) 9% 1·89 (1·66–2·14) <0·0001
IMD quintile 2
Number invited 3645 3703 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 768 (21%) 398 (11%) 10% 1·96 (1·73–2·22) <0·0001
Within 180 days of episode opened 825 (23%) 434 (12%) 11% 1·93 (1·71–2·17) <0·0001
IMD quintile 3
Number invited 2864 2978 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 686 (24%) 402 (13%) 10% 1·77 (1·56–2·01) <0·0001
Within 180 days of episode opened 734 (26%) 442 (15%) 11% 1·73 (1·53–1·95) <0·0001
IMD quintile 4
Number invited 1946 2028 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 488 (25%) 297 (15%) 10% 1·71 (1·48–1·98) <0·0001
Within 180 days of episode opened 519 (27%) 324 (16%) 11% 1·67 (1·45–1·92) <0·0001
IMD quintile 5 (least deprived)
Number invited 939 891 ·· ·· ··
Participation in screening
Within 90 days of irst ofered appointment 277 (29%) 178 (20%) 10% 1·48 (1·22–1·79) <0·0001
Within 180 days of episode opened 290 (31%) 194 (22%) 9% 1·42 (1·18–1·71) <0·0001
Data are number who participated (%) unless otherwise stated. IMD=2010 Index of Multiple Deprivation. RR=relative risk. Percentages have been rounded up.
Table 5: Participation at second invitation for all national IMD quintiles (from most to least deprived)
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sizes of the two groups. However, analysis was by 
intention to treat. Notably, the previous trial of second 
timed appointments for non-attenders had a similar 
imbalance, although in the other direction (more odd 
than even SX numbers).6
Nearly twice as many women in the intervention group 
than the control group participated in screening at 
second invitation. Although the intention-to-treat 
analysis led to more diluted results than less statistically 
cautious approaches, the improvement in participation 
in the intervention group was still substantial, as shown 
by our primary analysis. These results, therefore, support 
the NHSBSP policy of second timed appointments. The 
greater efect at prevalent screen than incident screen is 
important, since a stronger decline in participation over 
time has been reported at irst invitation than at 
subsequent invitations.1 The universal adoption of 
second timed appointments for non-attenders at irst 
invitation could go some way to rectifying this trend.
Evidence at the ecological and individual level from 
Europe and North America suggests that socioeconomic 
deprivation, often in conjunction with speciic ethnicity, 
is strongly associated with non-participation in breast 
cancer screening.11–16 Transport issues and di culties in 
getting to the screening appointment are cited as reasons 
for non-participation.12,14 Further detailed surveys of non-
participants are needed to improve our understanding of 
the barriers to participation. In our trial, women living in 
areas of higher deprivation showed a better response to 
the intervention than did women living in areas of lower 
deprivation. Thus, the practice of second timed 
appointments for non-attenders could address in part the 
socioeconomic gradient in delivery of the breast 
screening service.2,3 At the very least, this practice should 
not exacerbate the problem. This gradient needs to be 
addressed because the clinical stage of presentation 
tends to be later for women of lower socioeconomic 
status than for women of higher status, and is a factor 
that contributes to worse treatment outcomes.11 Arguably, 
a key factor responsible for women not attending their 
breast screening invitation might be car ownership, 
which is strongly correlated with socioeconomic status 
and positively associated with breast screening coverage.12 
A comparison of car ownership within the same IMD 
quintile between women who responded to their second 
timed appointment letter and women who did not could 
be interesting.
The greatest efect of the intervention was seen in 
southeast London, which had the highest proportion of 
women in the two lowest IMD quintiles. Plymouth, with 
the second largest proportion of study participants in the 
two lowest IMD quintiles, showed the smallest (albeit 
still substantial) efect of the intervention. In view of our 
indings, and the internationally observed socioeconomic 
gradient in participation in breast cancer screening,14–16 
our results could have relevance to other countries with 
organised screening programmes.
In all time-interval categories into which women were 
divided, the proportions of women who participated in 
screening increased in the intervention group versus the 
control by around the same relative factor for second 
timed appointments and there did not seem to be a trend 
between time since last screen and eicacy of the 
intervention, by contrast with indings reported by Stead 
and colleagues.6 However, the absolute efect declined 
with time since last attended screen, as has been reported 
previously, and relecting generally similar or larger 
relative efects but smaller absolute efects in those with 
a lower baseline participation. The number of second 
timed appointment letters that need to be ofered per 
additional participant increases for women whose last 
attendance at breast cancer screening was more than 
6 years before their current irst ofered appointment. Of 
course, fewer second timed appointment letters have to 
be issued than open letters per participant; however, 
reservation of the appointment time is the call on 
resources.
The economic implications of compulsorily extending 
the intervention to all women in the breast cancer 
screening programme will have to be examined before 
such a change in policy is made, because allocating time 
slots for ixed timed appointments has a cost in terms of 
resources. In most cases, overbooking for screening 
appointments is advised to minimise the waste from 
unused slots; our results suggest that increasing the 
overbooking ratio for second timed appointments for 
previous non-attenders would be safe. However, with the 
higher variability of the likelihood of participation in the 
second timed appointments, it would be prudent to mix 
small numbers of these within sessions with a majority 
of irst ofered appointments. Booking software (eg, 
Smart Clinics) is now available that overbooks by a 
magnitude depending on the likelihood of attendance. 
Ofering second timed appointments only to those who 
have attended in the 6 years previous to their irst ofered 
appointment might be a cost-efective approach, since it 
leads to fewer wasted appointments than in those who 
have not attended for a longer period. This strategy, 
however, raises questions of ethics and equity and should 
be considered further by the Department of Health and 
Public Health England to determine the appropriate 
policy for the programme. Scope also exists for qualitative 
research into the public acceptability of the policy of 
second timed appointments.
In other countries, such as Italy,17,18 ixed appointments 
rather than open invitations have been associated with 
improved participation in screening in general, not only 
for non-attenders. Other methods that can successfully 
increase participation in breast cancer screening are text 
message,19,20 postal,21 and telephone reminders;22 general 
practitioner endorsement;23,24 and the possibility to 
change appointments to out-of-oice hours.8 Second 
timed appointments for non-attenders could be 
implemented with these methods (eg, with the second 
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timed appointment letter ofering the opportunity to 
change to an out-of-hours time slot, or having primary 
care endorsement) and other interventions to improve 
delivery to all eligible women, with the ultimate goal of 
improving early detection of breast cancer in England 
and worldwide.
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